Abstract
The discovery of thromboxane A2 (TXA2) and prostacyclin, and the elucidation of their physiologic roles have brought new insights into atherogenesis and thrombogenesis [1–3]. In particular, the roles of these prostanoids in the pathogenesis of ischemic heart disease have recently been highlighted in relation to coronary thrombosis, vasospasm, and microcirculatory disturbances [4–7], and there has been much discussion regarding whether or not antiplatelet agents such as prostacyclin have preventive or curative effects in these conditions [8–11].
This is a preview of subscription content, log in via an institution to check access.
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Gryglewski RJ (1980) Prostaglandins, platelets and atherosclerosis. CRC Crit Rev Biochem 7: 291–338
Moncada S (1982) Prostacyclin and arterial wall biology. Arteriosclerosis 2: 193–207
Numano F (1981) Thromboxane A2 and atherosclerosis. In: de las Heras FG, Vega S (eds) Medicinal chemistry advances. Pergamon, Oxford, pp 131–140
Needleman P, Kalkarni PS, Raz A (1977) Coronary tone modulation; Formation and action of prostaglandins, endoperoxides and thromboxanes. Science 195: 409–412
Sobel M, Salzman EW, Davies GC, Handin RI, Sweeney J, Ploetz J, Kurland G (1981) Circulating platelet products in unstable angina pectoris. Circulation 63: 300–306
Moncada S, Vane JR (1982) Interrelationships between prostacyclin and thromboxane A2 metabolic activities of the lung. Ciba Foundation symposium’78. Excerpta Medica, Amsterdam, pp 165–183
Numano F, Nomura S, Aizawa T, Fujii J, Yajima M (1985) Prostacyclin and variant angina. Ann NY Acad Sci 454: 135–145
Moncada S (1983) Biology and therapeutic potential of prostacyclin. Stroke 14: 157–168
Numano F (1984) Cyclic nucleotides prostaglandins, and ischemic heart disease. In: Greengard P et al. (eds) Advances in cyclic nucleotides and protein phosphorylation research, vol 17. Raven, New York, pp 661–670
Vane JR (1983) Prostaglandins and the cardiovascular system. Brit Heart J 49: 405–409
Mehta J, Mehta P, Horalek C (1983) The sinificance of platelet-vessel wall prostaglandins equilibrium during exercise induced stress. Am Heart J 105: 895–900
Sasagawa S, Moriya K, Sugaya Y, Mitani J, Yajima M (1982) Effects of thromboxane A2 injection on the rabbit coronary artery. I. Physiological effects in healthy animals. Exp Mol Pathol 37: 111–117
Numano F, Yajima M, Nishiyama K, Shimokado K, Numano Fe, Sasagawa S, Moriya K (1982) Effects of thromboxane A2 injection on the rabbit coronary artery I. The production of infarcts in cholesterol fed animals. Exp Mol Pathol 37: 118–132
Numano F (1983) Prostaglandins, cyclic nucleotides and artherosclerosis. In: Schettler FG, Gotto AM, Middelhoff G, Habenicht HZE, Jurutka KR (eds) In: Atherosclerosis VI. Springer, Berlin Heidelberg New York, pp 704–707
Darius H (1985) Platelet and vascular effects of Iloprost (ZK 36374) and its stereoisomere ZK 36 375-two chemically stable prostacyclin analogues. In: Schrör K (ed) Prostaglandins and other eicosanoids in the cardiovascular system. Proceedings of the 2nd international symposium, Nürnberg-Fürth, 1984. Karger, Stuttgart, pp 454–464
Numano F, Omori K, Nishiyama K, Kishi Y, Shimokado K, Numano F, Yajima M, Maezawa H (1982) Plasma thromboxane B2 levels and atherosclerotic disorders. Paroi Arterielle-Arterial Wall/Par Arter VII: 99–106
Sekine M, Yajima M, Numano F (1985) Plasma 6-keto PGF1α levels in patients with vascular disorders. Vascular Med 3: 79–89
Numano F, Yajima M, Watanabe Y, Moriya K, Kuroiwa T, Shimokado K, Kishi Y, Maezawa H (1981) Microassay of cyclic nucleotides in vessel wall. V. Simultaneous assay of cyclic AMP and cyclic GMP. Exp Mol Pathol 34: 323–330
Lie JT, Holley KE, Kampa WR, Titus JL (1981) New histochemical method for morphologic diagnosis of early stages of myocardial ischemia. Mayo Clin Proc 46: 1210–1214
Takeuchi T, Kuriaki H (1955) Histochemical detection of Phosphorylase in animal tissues. J Histochem Cytochem 3: 153–160
Schrör K (1981) Possible role of prostaglandins in the regulation of coronary blood flow. Basic Res Cardiol 76: 239–249
Hirsch PD, Hills LD, Campbell WB, Firth BG, Willerson JT (1981) Release of prostaglandins and thromboxane into coronary circulation in patients with ischemic heart disease. N Engl J Med 304: 685–691
Lewy RI, Wiener L, Walinsky P, Lefer AM, Silver MJ, Smith JB (1980) Thromboxane release during pacing-induced angina pectoris: possible vasoconstrictor influence on the coronary vasculature. Circulation 61: 1165–1171
Yajima M, Nomura S, Namba K, Sekine M, Hosaka T, Numano F (1985) Plasma thromboxane B2, 6-keto PGF1α and cyclic nucleotides levels as related to treadmill exercise test in patients with ischemic heart disease. Jpn Circ J 49: 38–45
Numano F (1982) Antiplatelet therapy for ischemic heart disease. XI. world congress of cardiology, June 22, Moscow
Schrör K, Thiemermann C, Thomsen T, Ohlendorf R, Darius H, Gallenkämper W, Smith III EF (1984) Beneficial effect of iloprost in experimental myocardial infarction. In: Iloprost a novel prostacyclin analogue in cardiovascular disease. Scientific symposium, Düsseldorf. Schering AG, Berlin, pp 16–29
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1987 Springer-Verlag, Berlin Heidelberg
About this paper
Cite this paper
Numano, F. et al. (1987). Protective Effects of Iloprost Against Thromboxane-Induced Myocardial Infarction. In: Gryglewski, R.J., Stock, G. (eds) Prostacyclin and Its Stable Analogue Iloprost. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-71499-3_24
Download citation
DOI: https://doi.org/10.1007/978-3-642-71499-3_24
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-71501-3
Online ISBN: 978-3-642-71499-3
eBook Packages: Springer Book Archive